Kirkham, Bruce W. http://orcid.org/0000-0002-5110-3320
Egeberg, Alexander
Behrens, Frank
Pinter, Andreas
Merola, Joseph F.
Holzkämper, Thorsten
Gallo, Gaia
Ng, Khai Jing
Bolce, Rebecca
Schuster, Christopher
Nash, Peter
Puig, Luis
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
https://doi.org/10.1007/s13555-024-01147-7
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
https://doi.org/10.1016/s0140-6736(15)60125-8
Documents that mention this clinical trial
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
https://doi.org/10.1007/s13555-024-01147-7
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
https://doi.org/10.1016/s0140-6736(15)60125-8
Documents that mention this clinical trial
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
https://doi.org/10.1007/s13555-024-01147-7
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
https://doi.org/10.1016/s0140-6736(15)60125-8
Documents that mention this clinical trial
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Documents that mention this clinical trial
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
https://doi.org/10.1007/s13555-020-00383-x
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Documents that mention this clinical trial
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
https://doi.org/10.1007/s13555-023-01075-y
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Documents that mention this clinical trial
SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials
https://doi.org/10.1136/annrheumdis-2018-eular.2325
SAT0374 IXEKIZUMAB, WITH OR WITHOUT CONCOMITANT METHOTREXATE, IMPROVES THE SIGNS AND SYMPTOMS OF PSA FOR UP TO 52 WEEKS OF TREATMENT
https://doi.org/10.1136/annrheumdis-2019-eular.1240
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
https://doi.org/10.1136/annrheumdis-2018-215003
THU0314 Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
https://doi.org/10.1136/annrheumdis-2018-eular.2329
SAT0410 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2
https://doi.org/10.1136/annrheumdis-2020-eular.3994
OP0221 Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks
https://doi.org/10.1136/annrheumdis-2017-eular.2221
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
https://doi.org/10.1136/rmdopen-2017-000567
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2019-000928
SAT0316 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life in patients with active psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2331
AB0793 Efficacy of IXEKIZUMAB improving SF-36 scores in biologic dmard-naive patients with active psoriatic arthritis: results from a phase 3 study (SPIRIT-P1)
https://doi.org/10.1136/annrheumdis-2017-eular.2331
POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.567
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain (Post-results)
https://doi.org/10.1136/bmjopen-2019-032552
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
https://doi.org/10.1136/annrheumdis-2020-217372
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
https://doi.org/10.1136/annrheumdis-2021-222027
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
FRI0426 IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAïVE PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.1225
POS1045 Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement
https://doi.org/10.1136/annrheumdis-2021-eular.1570
AB0744 EFFICACY OF IXEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AXIAL PAIN STARTING BEFORE AGE 45: A SUBGROUP ANALYSIS OF SPIRIT-P1 AND SPIRIT-P2 PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1235
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002457
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
https://doi.org/10.1136/annrheumdis-2016-209709
THU0333 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1)
https://doi.org/10.1136/annrheumdis-2018-eular.2137
Documents that mention this clinical trial
SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials
https://doi.org/10.1136/annrheumdis-2018-eular.2325
SAT0341 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tnf inhibitors: 52-week results from a phase 3 study
https://doi.org/10.1136/annrheumdis-2018-eular.2352
SAT0374 IXEKIZUMAB, WITH OR WITHOUT CONCOMITANT METHOTREXATE, IMPROVES THE SIGNS AND SYMPTOMS OF PSA FOR UP TO 52 WEEKS OF TREATMENT
https://doi.org/10.1136/annrheumdis-2019-eular.1240
FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.2757
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
https://doi.org/10.1136/annrheumdis-2018-215003
THU0314 Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
https://doi.org/10.1136/annrheumdis-2018-eular.2329
AB0814 SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS: 3-YEAR RESULTS FROM SPIRIT-P2 TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.2087
FRI0357 IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2)
https://doi.org/10.1136/annrheumdis-2020-eular.1362
SAT0410 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2
https://doi.org/10.1136/annrheumdis-2020-eular.3994
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2019-000928
OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)
https://doi.org/10.1136/annrheumdis-2017-eular.1576
SAT0316 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life in patients with active psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2331
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain (Post-results)
https://doi.org/10.1136/bmjopen-2019-032552
POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.567
OP0110 IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO 1 OR 2 TUMOR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2019-eular.1479
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
https://doi.org/10.1136/rmdopen-2018-000692
SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.1580
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
https://doi.org/10.1136/annrheumdis-2021-222027
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
SAT0411 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)
https://doi.org/10.1136/annrheumdis-2020-eular.1482
FRI0426 IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAïVE PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.1225
POS1045 Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement
https://doi.org/10.1136/annrheumdis-2021-eular.1570
AB0744 EFFICACY OF IXEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AXIAL PAIN STARTING BEFORE AGE 45: A SUBGROUP ANALYSIS OF SPIRIT-P1 AND SPIRIT-P2 PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1235
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002457
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
https://doi.org/10.1136/annrheumdis-2016-209709
AB0944 Efficacy and safety of ixekizumab when used alone or in combination with conventional disease-modifying antirheumatic drugs (CDMARDS) in tnf-experienced patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2346
THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors
https://doi.org/10.1136/annrheumdis-2018-eular.2347
Documents that mention this clinical trial
LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS
https://doi.org/10.1136/annrheumdis-2019-eular.8709
FRI0345 HEAD-TO-HEAD STUDY EVALUATING THE COMBINED ACR50/PASI100 TREATMENT RESPONSE OF IXEKIZUMAB VERSUS ADALIMUMAB: INDIVIDUAL PATIENT DATA FROM A RANDOMIZED, OPEN-LABEL STUDY IN BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS THROUGH WEEK 52
https://doi.org/10.1136/annrheumdis-2020-eular.3996
AB0841 TARGET OUTCOMES IN PsA: SIMULTANEOUS ACHIEVEMENT of ACR50-PASI100 AND BEYOND: INSIGHTS FROM SPIRIT-H2H AT WEEK 24
https://doi.org/10.1136/annrheumdis-2020-eular.2884
POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.567
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 (Results)
https://doi.org/10.1136/annrheumdis-2020-217372
AB0802 SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.1365
AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis
https://doi.org/10.1136/annrheumdis-2022-eular.711
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
https://doi.org/10.1136/annrheumdis-2021-222027
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
https://doi.org/10.1136/annrheumdis-2019-215386
POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.5
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1514
OP0228 EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB (SPIRIT-H2H) WITH AND WITHOUT CONCOMITANT CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS
https://doi.org/10.1136/annrheumdis-2020-eular.4615
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 22 February 2023
Accepted: 13 April 2023
First Online: 3 July 2023